X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, PharmaEssentia will obtain the global exclusive rights to research, develop, manufacture and commercialize a myeloid immune checkpoint antibody candidate.
Lead Product(s): Myeloid Immune Checkpoint Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: WuXi Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 03, 2023
Details:
Under the agreement, Pint-Pharma will be obtaining and maintaining all marketing authorizations and commercializing BESREMi (ropeginterferon alfa-2b-njft), the first approved mono-pegylated proline interferon for polycythemia vera, a rare blood cancer, in Latin America.
Lead Product(s): Ropeginterferon-Alfa-2b
Therapeutic Area: Oncology Product Name: Besremi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pint Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 02, 2023
Details:
BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins. It is indicated for the polycythemia vera.
Lead Product(s): Ropeginterferon-Alfa-2b
Therapeutic Area: Oncology Product Name: BESREMi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
The collaboration will leverage Nona’s proprietary Harbour Mice® fully human antibody transgenic mice platform for the discovery of fully human monoclonal antibodies in classical two light and two heavy chain (H2L2) format, and heavy chain only (HCAb) formats.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Nona Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 12, 2023
Details:
BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins. It is being investigated for polycythemia vera.
Lead Product(s): Ropeginterferon-Alfa-2b
Therapeutic Area: Oncology Product Name: BESREMi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
The net proceeds from the offering will be used to to support growth plans and pipeline development, including Besremi (ropeginterferon alfa-2b-njft), an innovative monopegylated, long-acting interferon for the treatment of polycythemia vera (PV) in adults.
Lead Product(s): Ropeginterferon-Alfa-2b
Therapeutic Area: Oncology Product Name: Besremi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $462.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 21, 2023
Details:
BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins.
Lead Product(s): Ropeginterferon-Alfa-2b
Therapeutic Area: Oncology Product Name: BESREMi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
BESREMi (ropeginterferon alfa-2b-njft) binds to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular JAK1 and TYK2 and activator of transcription (STAT) proteins.
Lead Product(s): Ropeginterferon-Alfa-2b
Therapeutic Area: Oncology Product Name: BESREMi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2023
Details:
BESREMi (ropeginterferon alfa-2b-njft), is an innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks.
Lead Product(s): Ropeginterferon-Alfa-2b
Therapeutic Area: Oncology Product Name: Besremi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
P1101 (ropeginterferon alfa-2b-njft) is unique monopegylated, long-acting interferon to treat adults with polycythemia vera. Given well-established safety and efficacy profile demonstrated in prior studies, treatment may represent useful alternative to approved options for ET.
Lead Product(s): Ropeginterferon-Alfa-2b
Therapeutic Area: Oncology Product Name: P1101
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
